活性对照限制性比例失衡分析用于慢病药物警戒信号检测:以SGLT2抑制剂为例
本研究利用FDA不良事件报告系统,以二肽基肽酶4抑制剂为活性对照,对SGLT2抑制剂相关的5种潜在不良事件进行限制性比例失衡分析。结果显示,与二肽基肽酶4抑制剂相比,SGLT2抑制剂未检测到急性肾损伤和骨折的安全信号,但检测到泌尿生殖道感染、糖尿病酮症酸中毒和截肢的安全信号。该方法通过仔细选择对照可能减少假阳性信号和渠道偏倚。
要点
- 以二肽基肽酶4抑制剂为活性对照时,SGLT2抑制剂未显示急性肾损伤和骨折的安全信号。
- SGLT2抑制剂与泌尿生殖道感染、糖尿病酮症酸中毒和截肢的安全信号相关。
- 活性对照限制性比例失衡分析可能通过减少渠道偏倚降低假阳性信号。
核心结论
- 使用活性对照限制性比例失衡分析检测2型糖尿病药物安全信号,通过仔细选择对照可能减少假阳性信号并降低渠道偏倚。
研究设计与样本
- 利用FDA不良事件报告系统,评估SGLT2抑制剂与5种潜在不良事件的关联,采用3种参照组计算PRR和aROR。
主要发现
- 与二肽基肽酶4抑制剂相比,SGLT2抑制剂未检测到急性肾损伤安全信号(PRR 0.92 [0.81-1.04];aROR 0.78 [95%CI 0.72-0.85])。
- 与二肽基肽酶4抑制剂相比,SGLT2抑制剂未检测到骨折安全信号(PRR 0.44 [95%CI 0.17-1.15];aROR 0.74 [95%CI 0.61-0.91])。
- 与二肽基肽酶4抑制剂相比,SGLT2抑制剂检测到泌尿生殖道感染安全信号(PRR 2.75 [2.02-3.76];aROR 2.54 [2.26-2.86])。
- 与二肽基肽酶4抑制剂相比,SGLT2抑制剂检测到糖尿病酮症酸中毒安全信号(PRR 63.85 [39.37-103.53];aROR 91.49 [70.66-118.48])。
- 与二肽基肽酶4抑制剂相比,SGLT2抑制剂检测到截肢安全信号(PRR 52.60 [19.66-140.75];aROR 22.64 [15.32-33.42])。
临床怎么用
- 临床药师在评估SGLT2抑制剂安全性时,可参考活性对照限制性比例失衡分析的结果,关注泌尿生殖道感染、糖尿病酮症酸中毒和截肢风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Disproportionality analysis is a common pharmacovigilance tool to detect safety signals of type 2 diabetes medications from spontaneous drug reporting databases. The aim was to demonstrate the impact of using active-comparator restricted disproportionality analysis (ACR-DA), wherein the reference group is restricted to reports with a clinically appropriate active comparator. METHODS: Using reports from the Food and Drug Administration Adverse Event Reporting System, we assessed if sodium/glucose cotransporter 2 (SGLT2) inhibitors are associated with higher reporting of 5 potential adverse events: acute kidney injury, genitourinary tract infections, diabetic ketoacidosis, fractures, and amputations. For each adverse event, we calculated the proportional reporting ratio (PRR) and adjusted reporting odds ratio (aROR [95% confidence interval, CI]) using 3 types of reference groups: no SGLT2 inhibitor (background risk reference), other diabetes drugs (therapeutic class reference), and dipeptidyl peptidase 4 inhibitors (active comparator reference). RESULTS: Based on ACR-DA, we did not detect a safety signal for acute kidney injury (PRR 0.92 [0.81-1.04]; aROR 0.78 [95% CI 0.72-0.85]) or fractures (PRR 0.44[95% CI 0.17-1.15]; aROR 0.74 [95% CI 0.61-0.91]) associated with SGLT2 inhibitors compared to dipeptidyl peptidase 4 inhibitors. However, we detected safety signals for genitourinary tract infections (PRR 2.75[2.02-3.76]; aROR 2.54[2.26-2.86], diabetic ketoacidosis (PRR 63.85[39.37-103.53; aROR 91.49[70.66-118.48]), and amputations (PRR 52.60 [19.66-140.75]; aROR 22.64 [15.32-33.42]. CONCLUSION: The use of the proposed ACR-DA to detect safety signals of type 2 diabetes medications may reduce false positive safety signals through careful selection of the comparator which is expected to reduce channelling bias.
引用
- Alkabbani W, Gamble JM. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol. 2022. PMID: 34964156. doi:10.1111/bcp.15178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。